Skip to main content
Back
RDY logo

Dr. Reddy's Laboratories Limited

Data quality: 100%
RDY
NYSE Healthcare Drug Manufacturers - Specialty & Generic
$13.69
▼ $0.07 (-0.51%)
Mkt Cap: 11.40B
Day Range
$13.60 $13.86
52-Week Range
$12.26 $16.17
Volume
3,769,926
50D / 200D Avg
$13.97 / $14.25
Prev Close
$13.76

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.2 0.4
P/B 0.0 2.9
ROE % 18.4 3.7
Net Margin % 17.4 3.9
Rev Growth 5Y % 236.0 10.0
D/E 0.1 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2028 $68.20
$64.21 – $77.06
 400 B 1
FY2027 $55.78
$52.94 – $62.40
 360 B 2
FY2026 $61.47
$59.55 – $64.35
 350 B 2

Key Takeaways

Revenue grew 235.95% annually over 5 years — strong growth
ROE of 18.42% — decent returns on equity
Net margin of 17.37% shows strong profitability
Debt/Equity of 0.14 — conservative balance sheet
Generating 12.03B in free cash flow
P/E of 0.20 — trading at a low valuation

Growth

Revenue Growth (5Y)
235.95%
Revenue (1Y)16.61%
Earnings (1Y)1.54%
FCF Growth (3Y)-45.17%

Quality

Return on Equity
18.42%
ROIC14.17%
Net Margin17.37%
Op. Margin22.07%

Safety

Debt / Equity
0.14
Current Ratio1.92
Interest Coverage25.40

Valuation

P/E Ratio
0.20
P/B Ratio0.03
EV/EBITDA0.61
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16.61% Revenue Growth (3Y) 15.06%
Earnings Growth (1Y) 1.54% Earnings Growth (3Y) 12.01%
Revenue Growth (5Y) 235.95% Earnings Growth (5Y) 295.03%
Profitability
Revenue (TTM) 325.54B Net Income (TTM) 56.54B
ROE 18.42% ROA 11.47%
Gross Margin 58.50% Operating Margin 22.07%
Net Margin 17.37% Free Cash Flow (TTM) 12.03B
ROIC 14.17% FCF Growth (3Y) -45.17%
Safety
Debt / Equity 0.14 Current Ratio 1.92
Interest Coverage 25.40 Dividend Yield 0.01%
Valuation
P/E Ratio 0.20 P/B Ratio 0.03
P/S Ratio 0.04 PEG Ratio 10.58
EV/EBITDA 0.61 Dividend Yield 0.01%
Market Cap 11.40B Enterprise Value 43.51B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 325.54B 279.16B 245.88B 214.39B 2.56B
Net Income 56.54B 55.68B 45.07B 23.57B 232.21M
EPS (Diluted) 67.77 66.80 54.17 28.34 20.73
Gross Profit 190.43B 163.61B 139.34B 113.84B 1.30B
Operating Income 71.84B 67.73B 57.14B 29.48B 431.44M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 492.99B 387.52B 321.85B 292.83B 3.63B
Total Liabilities 155.82B 106.97B 90.86B 102.30B 1.26B
Shareholders' Equity 333.39B 280.55B 230.99B 190.53B 2.37B
Total Debt 46.77B 20.02B 13.47B 33.85B 414.53M
Cash & Equivalents 14.65B 7.11B 5.78B 14.85B 202.82M
Current Assets 250.11B 248.05B 204.25B 181.86B 2.03B
Current Liabilities 130.39B 96.04B 85.85B 94.02B 1.14B

Strategy Scores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#223 of 820
54
Growth Price/Sales Ratio Focus (Ken Fisher)
#432 of 616
22
Custom Contrarian Investing (David Dreman)
#585 of 658
6
Value Defensive Investing (Benjamin Graham)
#435 of 708
22

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Contrarian Investing (David Dreman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026